Skip to the main content.
Login Contact us

1 min read

Precision Oncology With AI-driven Workflow For Better Clinical Decisions

Precision Oncology With AI-driven Workflow For Better Clinical Decisions

The Radiological Society of North America's RSNA 2022 annual conference is on Nov 27 - Dec 1 in Chicago. Renowned as the world's largest medical imaging conference, over 400 educational and scientific sessions from every subspeciality, and 100+ industry presentations and demos showcasing the latest medical imaging technologies in CT, MRI, artificial intelligence (AI), 3D printing, and more will make up this tremendous event. Arterys' team will be in attendance at Booth 4719 and hoping to connect with those wanting to learn more about AI-driven workflows. 

RSNA 2022, celebrating its 108th year, is where "imaging, education, and collaboration come to life," with nearly 25,000 professionals from 116 countries expected. Arterys, recently acquired by precision medicine AI powerhouse Tempus Labs, is excited to present at the conference through our Director of Product Management, Maya Khalifé.  

AI-driven Workflows

 

dr mayaMaya's session, Precision Oncology: Empowering Radiologists With AI-driven Workflow for Better Clinical Decisions in Cancer Patients, will uncover the capabilities of Arterys' cloud-based intelligent diagnostic platform that combines clinical AI and workflow optimization to empower physicians to make more accurate & data-driven clinical decisions. 

Our presentation is on Tuesday, Nov 29, at 12:30 PM in McCormick Place's south hall Innovation Theater. It will showcase Arterys' AI-based oncology platform and demonstrate how it provides comprehensive cancer patient reporting and follow-up through an innovative and efficient workflow. Arterys enables physicians to make more informed treatment decisions and helps patients live longer and healthier lives.

Maya is a medical imaging enthusiast with 12+ years of experience combining medical imaging and machine learning to create healthcare solutions that impact patients’ lives. Her research work focused on image processing and machine learning applied to radiology. Her mission at Arterys is conceiving and building the radiology platform of the future to deliver tangible clinical value. 

Connect With Arterys at RSNA 2022

Maya and our team look forward to connecting and answering questions about AI in imaging workflows at our presentation and Booth 4719. Our solution is available to radiology departments via one medical imaging platform that delivers the highest return on investment and the lowest cost to implement management. We encourage you to schedule a demo to learn more at the show!

Book a Demo at RSNA 2022

Arterys And Therapixel Team Up For AI-powered Breast Cancer Solution

Arterys And Therapixel Team Up For AI-powered Breast Cancer Solution

Arterys, a Tempus company, has announced a US and EU distribution agreement with Therapixel, a medical imaging software company providing AI...

Read More
Arterys' Breast AI Suite: Transforming Breast Screening & Cancer Detection at SBI 2023

Arterys' Breast AI Suite: Transforming Breast Screening & Cancer Detection at SBI 2023

The 2023 Society of Breast Imaging (SBI) Breast Imaging Symposium is a must-attend event for radiologists and healthcare professionals involved in...

Read More
March Events: Procedural And Artificial Intelligence Developments In Oncology And Radiology

March Events: Procedural And Artificial Intelligence Developments In Oncology And Radiology

There are a lot of radiology conferences and events in March, and you can connect with the Arterys team at a number of them! Six specific events in...

Read More
Arterys has joined Tempus, and we are excited to reintroduce ourselves to you as Tempus Radiology.
Tempus is a leading technology company that is advancing precision medicine through the practical application of data and artificial intelligence in healthcare. By joining forces, Arterys’ product will be integrated into Tempus’ solutions, enabling providers to access a comprehensive patient view (now inclusive of radiology scans) and researchers to leverage this new data modality to optimize the drug development process.